Basic Research for the Clinical Use of Nuclear Factor-binding DNA Decoy for Inflammatory Skin Diseases
核因子结合 DNA 诱饵治疗炎症性皮肤病的临床应用基础研究
基本信息
- 批准号:14570800
- 负责人:
- 金额:$ 2.18万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2002
- 资助国家:日本
- 起止时间:2002 至 2004
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Thymus and activation-regulated chemokine (TARC/CCL17) is a potent chemokine, deeply associated with the pathogenesis of several inflammatory skin diseases, such as atopic dermatitis and bullous pemphigoid. Production of TARC from HaCaT keraitnocytes was synergistically induced by the stimulated with TNFα and IFNγ. NFkB and p38 are indispensable, EGF receptor was negatively involved, and STAT1 was not involved in this induction. PLA2 inhibitor, MAFP, and leukotrien B4 receptor inhibitor, LY, was also effective in suppressing TARC production. IMD, which was produced to suppress NFkB activation was effective in suppressing TARC production from HaCaT keratinocytes. Mechanical stress, are IL-15 are known to induce new lesions in psoriasis. They induced MAP kinase activation, proliferation, and attenuates apoptosis. Mechanical stress induced EGFR phosphorylation, ERK, and AP-1 activation. IL-15 induced ERK and PI3K activation. Suppression of these signaling molecules could be effective in treating inflammatory skin diseases such as psoriasis. We are planning to utilize these possibilities in vivo experiments.
趋化因子TARC/CCL 17是一种有效的趋化因子,与特应性皮炎和大疱性类天疱疮等炎症性皮肤病的发病机制密切相关。TNFα和IFNγ协同诱导HaCaT角膜基质细胞产生TARC。NFkB和p38是不可缺少的,EGF受体负性参与,而STAT 1不参与该诱导。PLA 2抑制剂MAFP和白三烯B4受体抑制剂LY也能有效抑制TARC的产生。产生IMD以抑制NFkB活化,其有效抑制HaCaT角质形成细胞的TARC产生。已知机械应力是IL-15在银屑病中诱导新的病变。它们诱导MAP激酶活化、增殖并减弱凋亡。机械应力诱导EGFR磷酸化、ERK和AP-1活化。IL-15诱导ERK和PI 3 K活化。抑制这些信号分子可能有效地治疗炎症性皮肤病,如牛皮癣。我们计划在体内实验中利用这些可能性。
项目成果
期刊论文数量(48)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A strong supprassor of cell proliferation, induces up-regulation of Keratin K6, one of the Inflammatory and proliferation associated Keratins.
细胞增殖的强抑制剂,可诱导角蛋白 K6 的上调,角蛋白 K6 是一种与炎症和增殖相关的角蛋白。
- DOI:
- 发表时间:2002
- 期刊:
- 影响因子:0
- 作者:Hattori N;Komine M;et al.
- 通讯作者:et al.
Yano S, Komine M, et al.: "Mechanical Stretching In Vitro Regulates Signal Transduction Pathways and Cellular Proliferation in Human Epidermal Keratinocytes"J Invest Dermatol. (in press). (2004)
Yano S、Komine M 等人:“体外机械拉伸调节人表皮角质形成细胞的信号转导途径和细胞增殖”J Invest Dermatol。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kagami S, Kakinuma T, et al.: "Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis"Clin Exp Immunol. 134(2). 309-313 (2003)
Kagami S、Kakinuma T 等人:“在特应性皮炎患者中,eotaxin-3/CCL26 的血清水平显着升高,但eotaxin-2/CCL24 的血清水平没有显着升高”Clin Exp Immunol。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Significane elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, inpatients with atopic dermatitis.
特应性皮炎住院患者血清eotaxin-3/CCL26水平显着升高,但eotaxin-2/CCL24未升高。
- DOI:
- 发表时间:2003
- 期刊:
- 影响因子:0
- 作者:Kagami S;Kakinuma T;et al.
- 通讯作者:et al.
Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris
- DOI:10.1067/mai.2003.114
- 发表时间:2003-03-01
- 期刊:
- 影响因子:14.2
- 作者:Kakinuma, T;Saeki, H;Tamaki, K
- 通讯作者:Tamaki, K
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KOMINE Mayumi其他文献
KOMINE Mayumi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KOMINE Mayumi', 18)}}的其他基金
The role of IL-33 and its reseptor in contact hypersensitivity reaction
IL-33及其受体在接触性超敏反应中的作用
- 批准号:
23591652 - 财政年份:2011
- 资助金额:
$ 2.18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Regulation of chemokine production in inflammatory cutaneous disorders
炎症性皮肤病中趋化因子产生的调节
- 批准号:
18591236 - 财政年份:2006
- 资助金额:
$ 2.18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Identifying the role of interferon and interferon-regulated chemokines in stress-induced immunosuppression in triple negative breast cancer
确定干扰素和干扰素调节的趋化因子在三阴性乳腺癌应激诱导的免疫抑制中的作用
- 批准号:
10727051 - 财政年份:2023
- 资助金额:
$ 2.18万 - 项目类别:
Role of chemokines in neuronal function and survival
趋化因子在神经元功能和存活中的作用
- 批准号:
10610620 - 财政年份:2023
- 资助金额:
$ 2.18万 - 项目类别:
Impact of chemokines in development of rare vasculopathies
趋化因子对罕见血管病发展的影响
- 批准号:
23K15109 - 财政年份:2023
- 资助金额:
$ 2.18万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Targeting Aberrant Expression of Cytokines/Chemokines for an Inflammatory Nephritis Cure
针对细胞因子/趋化因子的异常表达来治疗炎症性肾炎
- 批准号:
10525534 - 财政年份:2022
- 资助金额:
$ 2.18万 - 项目类别:
Targeting Aberrant Expression of Cytokines/Chemokines for an Inflammatory Nephritis Cure
针对细胞因子/趋化因子的异常表达来治疗炎症性肾炎
- 批准号:
10651843 - 财政年份:2022
- 资助金额:
$ 2.18万 - 项目类别:
Regulation and function of Duffy antigen receptor for chemokines (DARC) in primary endothelial cells
原代内皮细胞达菲抗原趋化因子受体 (DARC) 的调节和功能
- 批准号:
RGPIN-2020-04299 - 财政年份:2022
- 资助金额:
$ 2.18万 - 项目类别:
Discovery Grants Program - Individual
RNA virus capture of host chemokines: Understanding novel viral mechanisms of immune manipulation
RNA病毒捕获宿主趋化因子:了解免疫操纵的新病毒机制
- 批准号:
10452788 - 财政年份:2022
- 资助金额:
$ 2.18万 - 项目类别:
RNA virus capture of host chemokines: Understanding novel viral mechanisms of immune manipulation
RNA病毒捕获宿主趋化因子:了解免疫操纵的新病毒机制
- 批准号:
10551229 - 财政年份:2022
- 资助金额:
$ 2.18万 - 项目类别:
Using high T-bet-expressing cells and Serum Chemokines as Indicators of Disease Severity in Sarcoidosis
使用高 T-bet 表达细胞和血清趋化因子作为结节病疾病严重程度的指标
- 批准号:
10684920 - 财政年份:2021
- 资助金额:
$ 2.18万 - 项目类别:
Targeting immunosuppressive chemokines for enhanced response to radiotherapy in squamous cell cancers
靶向免疫抑制趋化因子以增强鳞状细胞癌放疗反应
- 批准号:
453487 - 财政年份:2021
- 资助金额:
$ 2.18万 - 项目类别:
Operating Grants